Cargando…
Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin α: results of a phase I randomized, placebo-controlled trial
INTRODUCTION: Pateclizumab (MLTA3698A) is a humanized mAb against lymphotoxin α (LTα), a transiently expressed cytokine on activated B and T cells (Th1, Th17), which are implicated in rheumatoid arthritis (RA) pathogenesis. This study was conducted to assess the safety, tolerability, < NOTE: For...
Autores principales: | Emu, Brinda, Luca, Diana, Offutt, Carolyn, Grogan, Jane L, Rojkovich, Bernadette, Williams, Marna B, Tang, Meina T, Xiao, Jim, Lee, June H, Davis, John C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3392792/ https://www.ncbi.nlm.nih.gov/pubmed/22225620 http://dx.doi.org/10.1186/ar3554 |
Ejemplares similares
-
Efficacy and safety of pateclizumab (anti-lymphotoxin-α) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study)
por: Kennedy, William P, et al.
Publicado: (2014) -
In Vivo Depletion of Lymphotoxin-Alpha Expressing Lymphocytes Inhibits Xenogeneic Graft-versus-Host-Disease
por: Chiang, Eugene Y., et al.
Publicado: (2012) -
Genomic organization and phylogenetic utility of deer mouse (Peromyscus maniculatus) lymphotoxin-alpha and lymphotoxin-beta
por: Richens, Tiffany, et al.
Publicado: (2008) -
Lymphotoxin-sensitive microenvironments in homeostasis and inflammation
por: Boulianne, Bryant, et al.
Publicado: (2012) -
Secreted Lymphotoxin-α Is Essential for the Control of an Intracellular Bacterial Infection
por: Roach, Daniel R., et al.
Publicado: (2001)